Wild ginseng cambial meristematic cells ameliorate hepatic steatosis and mitochondrial dysfunction in high-fat diet-fed mice

J Pharm Pharmacol. 2016 Jan;68(1):119-27. doi: 10.1111/jphp.12487.

Abstract

Objectives: The aim of this study was to determine the protective mechanisms of wild ginseng cambial meristematic cells (CMCs) on non-alcoholic fatty liver disease in high-fat diet (HFD)-fed mice.

Methods: Male C57BL/6 mice received either normal-fat diet or HFD for 10 weeks along with wild ginseng CMCs (75, 150 and 300 mg/kg) or vehicle (0.5% carboxyl methyl cellulose) by oral administration once a day. Triglyceride and total cholesterol contents were measured in liver and serum samples. Parameters for hepatic lipid metabolism and mitochondria biogenesis were assessed.

Key findings: Treatment with wild ginseng CMCs markedly attenuated body weight, serum and hepatic lipid contents, and serum aminotransferase activity. While wild ginseng CMCs attenuated the increases in sterol regulatory element-binding transcription factor 1 (SREBP-1) and carbohydrate-responsive element-binding protein (ChREBP) expression, it enhanced the increases in carnitine palmitoyltransferase 1A (CPT1A) and peroxisome proliferator-activated receptor alpha (PPAR-α) expression. HFD decreased glutamate dehydrogenase activity and glutathione content, and increased lipid peroxidation, which were all attenuated by wild ginseng CMCs. Furthermore, wild ginseng CMCs enhanced mitochondrial biogenesis-related factors, including peroxisome proliferator-activated receptor-γ co activator 1α (PGC1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM).

Conclusions: Wild ginseng CMCs protect against HFD-induced liver injury, which prevents lipid accumulation and mitochondrial oxidative stress, and enhances mitochondrial biogenesis.

Keywords: de-novo lipogenesis; mitochondrial biogenesis; non-alcoholic fatty liver disease; wild ginseng cambial meristematic cells; β-oxidation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
  • Body Weight / drug effects
  • Carnitine O-Palmitoyltransferase / metabolism
  • Cholesterol / blood
  • Cholesterol / metabolism
  • DNA-Binding Proteins / metabolism
  • Diet, High-Fat / adverse effects*
  • Fatty Liver / blood
  • Fatty Liver / drug therapy*
  • Fatty Liver / metabolism
  • Glutathione / metabolism
  • High Mobility Group Proteins / metabolism
  • Lipid Metabolism / drug effects
  • Lipid Peroxidation / drug effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondrial Diseases / blood
  • Mitochondrial Diseases / drug therapy*
  • Mitochondrial Diseases / metabolism
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / drug therapy
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Nuclear Proteins / metabolism
  • Nuclear Respiratory Factor 1 / metabolism
  • Organelle Biogenesis
  • PPAR alpha / metabolism
  • Panax / chemistry*
  • RNA-Binding Proteins / metabolism
  • Sterol Regulatory Element Binding Protein 1 / metabolism
  • Transaminases / metabolism
  • Transcription Factors / metabolism
  • Triglycerides / blood

Substances

  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
  • DNA-Binding Proteins
  • High Mobility Group Proteins
  • Mlxipl protein, mouse
  • Nrf1 protein, mouse
  • Nuclear Proteins
  • Nuclear Respiratory Factor 1
  • PPAR alpha
  • RNA-Binding Proteins
  • Sterol Regulatory Element Binding Protein 1
  • Tfam protein, mouse
  • Transcription Factors
  • Triglycerides
  • Cholesterol
  • Carnitine O-Palmitoyltransferase
  • Transaminases
  • Glutathione

Associated data

  • GENBANK/D12492
  • GENBANK/S10026
  • GENBANK/V10001